The company’s studies have evidence that supports using the WATS device to monitor patients who have received ablation therapy for esophageal pre-cancer.
A WATS biopsy collects a wide area of tissue that is then given a computer-assisted 3-D analysis to pinpoint problematic cells.
Representatives from the company will present their clinical data at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course this weekend.
More Articles on Gastroenterology:
Gastric Cancer Foundation, American Gastroenterological Association Team Up to Provide $2.25M in Research Grants
Today Olympus Launches New Ultrasound Gastrovideoscope
Jay Monahan Center for Gastrointestinal Health Names Dr. Fleice Schnoll-Sussman Director
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
